Point72 Asia Singapore Pte. Ltd. Makes New $182,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Point72 Asia Singapore Pte. Ltd. acquired a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,971 shares of the medical research company’s stock, valued at approximately $182,000.

A number of other institutional investors also recently modified their holdings of EW. Price T Rowe Associates Inc. MD increased its stake in Edwards Lifesciences by 57.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after purchasing an additional 2,390,137 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of Edwards Lifesciences by 197.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock worth $262,815,000 after purchasing an additional 2,286,119 shares in the last quarter. Sands Capital Management LLC grew its stake in shares of Edwards Lifesciences by 34.6% in the 4th quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock valued at $465,407,000 after buying an additional 1,567,526 shares during the period. CCLA Investment Management increased its position in Edwards Lifesciences by 100,739.7% in the 1st quarter. CCLA Investment Management now owns 1,406,714 shares of the medical research company’s stock valued at $134,092,000 after buying an additional 1,405,319 shares in the last quarter. Finally, Swedbank AB acquired a new position in Edwards Lifesciences during the 1st quarter worth approximately $124,511,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $65.77 on Friday. The company’s fifty day moving average price is $68.58 and its 200-day moving average price is $82.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. The firm has a market capitalization of $39.63 billion, a price-to-earnings ratio of 28.35, a PEG ratio of 2.80 and a beta of 1.13. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the prior year, the firm earned $0.66 earnings per share. The firm’s revenue was up 6.7% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent research reports. Citigroup boosted their price objective on Edwards Lifesciences from $105.00 to $106.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. TD Cowen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $100.00 to $70.00 in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, July 25th. Piper Sandler decreased their target price on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research report on Thursday, July 25th. Finally, Robert W. Baird cut shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $102.00 to $70.00 in a research report on Thursday, July 25th. Sixteen analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $79.82.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,133,916.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock worth $1,218,138 in the last quarter. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.